Intended for healthcare professionals


Sixty seconds on . . . the cost of semaglutide

BMJ 2023; 382 doi: (Published 31 August 2023) Cite this as: BMJ 2023;382:p2009
  1. Zosia Kmietowicz
  1. The BMJ

The new wonder drug?

Some have called it that. The injectable glucagon like peptide-1 (GLP-1) receptor agonist, also called by its brand name Wegovy, is in high demand among celebrities wanting to lose weight and doctors wanting to prescribe it to patients with obesity or type 2 diabetes, for whom the drug was originally licensed.

Can’t it prevent heart attacks too?

Apparently. Results of the Select trial of over 17 000 people showed that semaglutide reduced the risk of major cardiovascular events …

View Full Text

Log in

Log in through your institution


* For online subscription